Provided by Tiger Trade Technology Pte. Ltd.

SBP GROUP

5.595
+0.2053.80%
Volume:142.80M
Turnover:793.62M
Market Cap:104.53B
PE:36.95
High:5.635
Open:5.365
Low:5.310
Close:5.390
52wk High:9.017
52wk Low:4.190
Shares:18.68B
HK Float Shares:18.68B
Volume Ratio:1.26
T/O Rate:0.76%
Dividend:0.12
Dividend Rate:2.19%
EPS(LYR):0.151
ROE:14.07%
ROA:7.51%
PB:2.75
PE(LYR):36.95
PS:2.66

Loading ...

Sino Biopharmaceutical Stock Slips 5.3% in Hong Kong

Dow Jones
·
Jul 17

Movement Alert|Sino Biopharmaceutical Falls 3.04% in Regular Trading, Pharmaceutical Sector Broadly Under Pressure

Market Focus
·
Jul 17

Stock Track | Sino Biopharmaceutical Soars 5.09% Intraday on TRD205 Breakthrough Therapy Designation and Morgan Stanley Earnings Upgrade

Stock Track
·
Jul 15

Movement Alert|Sino Biopharmaceutical Rises 3.72% in Regular Trading, TRD205 Granted Breakthrough Therapy Designation Plus Morgan Stanley Raises Earnings Estimates

Market Focus
·
Jul 15

Sino Biopharmaceutical Says Trd205 Granted Breakthrough Therapy Designation by China's

Reuters
·
Jul 14

Sino Biopharma Unit Gets Breakthrough Therapy Designation for Neuropathic Pain Drug in China

MT Newswires Live
·
Jul 14

SBP GROUP's TRD205 AT2R Antagonist Receives Breakthrough Therapy Designation from CDE

Stock News
·
Jul 14

Sino Biopharmaceutical - Trd205 Granted Breakthrough Therapy Designation by China's Cde After Phase Ii Trial for Cpsnp

THOMSON REUTERS
·
Jul 14

Sino Biopharmaceutical Stock Slips 1.0% in Hong Kong, Underperforms Competitors

Dow Jones
·
Jul 14

Morgan Stanley Adjusts Earnings Per Share Forecasts for SBP GROUP Through 2028, Reiterates 'Overweight' Rating

Stock News
·
Jul 14

Sino Biopharm Files HKEX Next-day Return Disclosing Share Buyback Cancellation at HKD 4.46 Each

Reuters
·
Jul 13

SBP Group receives CDE acceptance for TQB3454 NDA targeting IDH1-mutant biliary tract cancer

Bulletin Express
·
Jul 10

Innovative Drug TQB3454 from SBP Group's Subsidiary Seeks Market Approval in China

Stock News
·
Jul 10

Sino Biopharm Says China Regulator Accepts NDA for Tqb3454 IDH1 Inhibitor in Biliary Tract Cancer

Reuters
·
Jul 10

Sino Biopharmaceutical - China's Cde Accepts Nda for Tqb3454 Tablet 'idh1 Inhibitor' for Advanced BTC with Idh1 Mutations

THOMSON REUTERS
·
Jul 10

Sino Biopharmaceutical Stock Advances 3.8% in Hong Kong, Outperforms Competitors

Dow Jones
·
Jul 10

Stock Track | Sino Biopharmaceutical Soars 5.00% Intraday on AstraZeneca and GSK Partnerships and NDA Milestone

Stock Track
·
Jul 10

Movement Alert|Sino Biopharmaceutical Rises 3.2% in Regular Trading, AstraZeneca and GSK Dual Partnerships Continue to Boost Sentiment

Market Focus
·
Jul 10

Why Sino Biopharmaceutical (SEHK:1177) Is Up 8.2% After New Global Respiratory Deals And NDA Milestone

Simply Wall St.
·
Jul 10

Sino Biopharmaceutical Stock Rises 3.7% in Hong Kong, Outperforms Competitors

Dow Jones
·
Jul 09